LeMaitre Vascular, Inc. logo

LeMaitre Vascular, Inc.

LMAT

NASDAQHealthcareMedical - Instruments & Supplies

Previous close

$81.86

−$0.46 · -0.56%

Aug 21, 4:00 PM ET

LMAT company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Buy

Favorable setup — positive multi-factor alignment

Valuation

71

Undervalued

Momentum

60

Neutral

Sentiment

71

Bullish

Risk resilience

69

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Operating worldwide, LeMaitre Vascular, Inc. specializes in the development, distribution, and maintenance of medical devices and implants for treating peripheral vascular disease. Its product portfolio encompasses a range of catheters, including angioscopes, which are fiberoptic tools for internal blood vessel visualization; embolectomy catheters for removing blood clots from arteries or veins; occlusion catheters that temporarily halt blood flow; perfusion catheters for infusing blood and other fluids into the vasculature; and thrombectomy catheters, featuring a silicone balloon for extracting venous thrombi. The company also furnishes carotid shunts, designed to temporarily redirect blood flow to the brain during carotid endarterectomy surgery to clear arterial plaque. Another offering is radiopaque tape, a medical-grade adhesive applied externally to help interventionists precisely cross-reference skin locations with underlying anatomical features like vessels or lesions. Further products include valvulotomes, instruments used to cut or disrupt valves within the saphenous vein, enabling it to function as an arterial bypass to carry blood past diseased arteries to the lower leg or foot. Additionally, LeMaitre supplies vascular grafts for bypassing or replacing compromised arteries. Moreover, the company provides vascular and cardiac patches for post-surgical vessel closure. Its closure systems employ titanium clips for connecting vessels, offering an alternative to traditional sutures. Products are distributed via both its direct sales force and a network of distributors. Founded in 1983 as Vascutech, Inc., the company rebranded as LeMaitre Vascular, Inc. in April 2001. It is headquartered in Burlington, Massachusetts.

Industry
Medical - Instruments & Supplies
Sector
Healthcare
Headquarters
US
CEO
George W. LeMaitre
Listed since
Oct 19, 2006
Employees
651

Market position

Day range

Current $81.86

52-week range

Current $81.86

Open
$82.37
Previous close
$82.32
Volume
419.89K
1.27× average
Average volume
329.63K
Average daily volume
Market cap
1.87B USD
Beta
0.52
Market reference 1
50-day average
$94.1288
-13.03% below average
200-day average
$95.3477
-14.15% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
1.99B USD
P/E (TTM)
28.23×
P/B (TTM)
4.45×
P/S (TTM)
7.13×
EV / EBITDA
21.96×
Earnings yield
3.14%
Free cash flow yield
4.06%
Dividend yield
1.16%

Profitability & efficiency

Gross margin
72.90%
Operating margin
29.46%
Net margin
25.02%
Return on equity
14.67%
Return on assets
9.38%
Return on invested capital
8.96%

Financial health

Debt / equity
0.45×
Current ratio
12.89×
Altman Z-score
7.25
Piotroski F-score
6 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends77%54%30%7%Gross margin, FY2021: 65.65%Gross margin, FY2022: 64.89%Gross margin, FY2023: 65.66%Gross margin, FY2024: 68.63%Gross margin, FY2025: 71.53%Operating margin, FY2021: 23.59%Operating margin, FY2022: 16.60%Operating margin, FY2023: 18.97%Operating margin, FY2024: 23.77%Operating margin, FY2025: 27.21%Net margin, FY2021: 17.42%Net margin, FY2022: 12.77%Net margin, FY2023: 15.56%Net margin, FY2024: 20.03%Net margin, FY2025: 23.13%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 65.65%. Gross margin FY2022 64.89%. Gross margin FY2023 65.66%. Gross margin FY2024 68.63%. Gross margin FY2025 71.53%. Operating margin FY2021 23.59%. Operating margin FY2022 16.60%. Operating margin FY2023 18.97%. Operating margin FY2024 23.77%. Operating margin FY2025 27.21%. Net margin FY2021 17.42%. Net margin FY2022 12.77%. Net margin FY2023 15.56%. Net margin FY2024 20.03%. Net margin FY2025 23.13%.

Income trends

Revenue

249.6M USD+13.53%

Operating income

67.91M USD+29.96%

Net income

57.73M USD+31.10%
Income trends across reported periods272.5M USD180.91M USD89.33M USD−2.26M USDRevenue, FY2021: 154.42M USDRevenue, FY2022: 161.65M USDRevenue, FY2023: 193.48M USDRevenue, FY2024: 219.86M USDRevenue, FY2025: 249.6M USDOperating income, FY2021: 36.43M USDOperating income, FY2022: 26.83M USDOperating income, FY2023: 36.71M USDOperating income, FY2024: 52.26M USDOperating income, FY2025: 67.91M USDNet income, FY2021: 26.91M USDNet income, FY2022: 20.64M USDNet income, FY2023: 30.11M USDNet income, FY2024: 44.04M USDNet income, FY2025: 57.73M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 154.42M USD. Revenue FY2022 161.65M USD. Revenue FY2023 193.48M USD. Revenue FY2024 219.86M USD. Revenue FY2025 249.6M USD. Operating income FY2021 36.43M USD. Operating income FY2022 26.83M USD. Operating income FY2023 36.71M USD. Operating income FY2024 52.26M USD. Operating income FY2025 67.91M USD. Net income FY2021 26.91M USD. Net income FY2022 20.64M USD. Net income FY2023 30.11M USD. Net income FY2024 44.04M USD. Net income FY2025 57.73M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue249.6M USD219.86M USD193.48M USD161.65M USD154.42M USD
Cost of goods sold71.06M USD68.96M USD66.44M USD56.76M USD53.04M USD
Gross profit178.54M USD150.9M USD127.05M USD104.9M USD101.38M USD
Research and development14.14M USD15.65M USD16.97M USD13.29M USD11.8M USD
Selling, general, and administrative96.49M USD83M USD72.89M USD61.67M USD53.16M USD
Operating expenses110.63M USD98.65M USD90.34M USD78.07M USD64.96M USD
Interest income13.09M USD4.95M USD3.08M USD986K USD197K USD
Interest expense5.18M USD205K USD2.22M USD
Depreciation and amortization10.42M USD9.67M USD9.52M USD9.43M USD9.48M USD
Operating income67.91M USD52.26M USD36.71M USD26.83M USD36.43M USD
Net income57.73M USD44.04M USD30.11M USD20.64M USD26.91M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
73%
8 beats, 2 misses, 1 met estimate
Average EPS surprise
+4.34%
11 comparable reports
Latest EPS result
0.74
Estimate 0.81 · Miss by 8.30%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.850.710.580.44Q1 '25MetQ2 '25MissQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26MissQ4 '26Estimate
Q1 2025, reported Feb 27, 2025: actual 0.49, estimate 0.49, surprise 0.00%, Met estimate. Q2 2025, reported May 1, 2025: actual 0.48, estimate 0.5, surprise -4.00%, Miss. Q3 2025, reported Aug 5, 2025: actual 0.6, estimate 0.57, surprise +5.26%, Beat. Q4 2025, reported Nov 6, 2025: actual 0.62, estimate 0.564, surprise +9.93%, Beat. Q1 2026, reported Feb 25, 2026: actual 0.68, estimate 0.67, surprise +1.49%, Beat. Q2 2026, reported May 5, 2026: actual 0.68, estimate 0.66, surprise +3.03%, Beat. Q3 2026, reported Aug 4, 2026: actual 0.74, estimate 0.807, surprise -8.30%, Miss. Q4 2026, reported Nov 5, 2026: actual —, estimate 0.69, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates74.33M67.17M60.02M52.86MQ1 '25MissQ2 '25BeatQ3 '25BeatQ4 '25MissQ1 '26BeatQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Feb 27, 2025: actual 55.72M USD, estimate 55.99M USD, surprise -0.48%, Miss. Q2 2025, reported May 1, 2025: actual 59.87M USD, estimate 57.61M USD, surprise +3.92%, Beat. Q3 2025, reported Aug 5, 2025: actual 64.23M USD, estimate 60.9M USD, surprise +5.48%, Beat. Q4 2025, reported Nov 6, 2025: actual 61.05M USD, estimate 62.18M USD, surprise -1.82%, Miss. Q1 2026, reported Feb 25, 2026: actual 64.45M USD, estimate 62.82M USD, surprise +2.60%, Beat. Q2 2026, reported May 5, 2026: actual 66.55M USD, estimate 66.67M USD, surprise -0.18%, Miss. Q3 2026, reported Aug 4, 2026: actual 70.38M USD, estimate 71.47M USD, surprise -1.53%, Miss. Q4 2026, reported Nov 5, 2026: actual —, estimate 67.39M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

20 ratings
Strong buy00%
Buy1470%
Hold630%
Sell00%
Strong sell00%

Recent analyst actions

10 institutions
Roth CapitalmaintainBuy
Cantor FitzgeraldmaintainNeutral
Citizens Capital MarketsmaintainBuy
Lake StreetmaintainBuy
OppenheimermaintainOutperform

Corporate actions

Annual dividends per share

Cash distributions grouped by calendar year; partial years are marked.

$0.80

2025 complete year+81.8% since 2021

2026 partial: $0.75

* Partial calendar year in the available dividend history.

Corporate action history

Dividend

Ex-dividend Aug 20, 2026

$0.25

Quarterly

Record Aug 20, 2026 · Payment Sep 3, 2026

Dividend

Ex-dividend May 21, 2026

$0.25

Quarterly

Record May 21, 2026 · Payment Jun 4, 2026

Dividend

Ex-dividend Mar 12, 2026

$0.25

Quarterly

Record Mar 12, 2026 · Payment Mar 26, 2026

Dividend

Ex-dividend Nov 20, 2025

$0.20

Quarterly

Record Nov 20, 2025 · Payment Dec 4, 2025

Dividend

Ex-dividend Aug 21, 2025

$0.20

Quarterly

Record Aug 21, 2025 · Payment Sep 4, 2025

Dividend

Ex-dividend May 15, 2025

$0.20

Quarterly

Record May 15, 2025 · Payment May 29, 2025

LMAT peers

Continue in GoAI

Research LMAT

research.disclaimer